FORUM Pharmaceuticals Inc. Relocates Corporate Headquarters to State-of-the-Art Facility in Waltham, Massachusetts

FORUM Pharmaceuticals Inc., a biopharmaceutical company singularly focused on the development and delivery of innovative medicines to treat serious brain diseases, today announced that it has relocated its corporate headquarters to a 112,500 square foot, state-of-the-art facility located at 225 Second Avenue in Waltham, Mass. The move consolidates FORUM’s operations into a single centralized location that houses corporate offices, clinical development and research laboratories. Prior to the move, FORUM conducted business from two locations in Watertown, Mass. and Brighton, Mass. The Company also maintains a small European office in The Netherlands.

“We are excited to be located under one roof in Waltham, as it facilitates daily interaction of our development and commercial teams with research scientists to drive continued innovation in FORUM’s focused product pipeline that targets serious brain diseases such as schizophrenia, Alzheimer’s disease and frontotemporal dementia,” said Deborah Dunsire, M.D., President and Chief Executive Officer of FORUM Pharmaceuticals. “With our lead product candidate, encenicline, in two large Phase 3 clinical trials for schizophrenia and Alzheimer’s disease, our genetically-targeted therapy, FRM-0334, in a Phase 2 trial for a genetic variant of frontotemporal dementia, as well as our robust drug discovery efforts, we need to plan for FORUM’s future growth as we bring new medicines to patients. This state-of-the-art, custom designed facility is a critical next step in our advancement. We look forward to being an active and productive member of the Waltham business community.”

The new address for FORUM Pharmaceuticals is 225 Second Avenue, Waltham, Mass., 02451. FORUM’s main telephone number of (617) 225-4250 remains unchanged with the move.

The property at 225 Second Avenue in Waltham, Mass. is owned and operated by an affiliate of Alexandria Real Estate Equities, Inc. (NYSE: ARE). Robert Richards, Partner, Transwestern | RBJ represented FORUM in the transaction. Building ownership was represented internally by Thomas Andrews, Executive Vice President, and Dan Cordeau, Vice President of Leasing.

About FORUM Pharmaceuticals Inc.

FORUM Pharmaceuticals Inc. (“FORUM Pharmaceuticals” or “FORUM”) is dedicated to developing groundbreaking medicines in support of all those who are affected by or caring for people with serious brain disease, to help them live fuller, more enriching lives. The Company’s robust and diverse pipeline is focused on discovering and developing new treatments for important neurodegenerative diseases that explore novel mechanisms of action to potentially alter the progression of brain disease and provide improvement in cognitive and overall function. FORUM’s lead compound, encenicline, is currently being evaluated in separate ongoing Phase 3 clinical trial programs: COGNITIV SZ, which looks to improve cognitive impairment in patients with schizophrenia, and COGNITIV AD, which aims to improve cognition in patients with Alzheimer’s disease. The Company is also developing genetically targeted therapies, including FRM-0334 for the potential treatment of the ultra-orphan, rare disease frontotemporal dementia. Privately owned, FORUM Pharmaceuticals is based in Waltham, Mass. For more information about FORUM, visit www.forumpharma.com.

FORUM Pharmaceuticals and the FORUM octagon logo are trademarks of FORUM Pharmaceuticals Inc.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150518005100/en/